Imatinib Mesylate from Japan
Imatinib mesylate, tyrosine kinase inhibitor with pyrimidine and piperazine rings (N hetero-atoms only), used in leukemia treatment. HTS 2933.99.8290 for bulk API as other aromatic heterocyclic nitrogen compounds. Key oncology pharmaceutical intermediate.
Duty Rate — Japan → United States
21%
Rate breakdown
9903.04.628.5%Patented pharmaceutical articles that are the product of Japan, of a European Union member country, of South Korea, of Switzerland, or of Liechtenstein as provided for in subdivisions (c) and (f) of U.S. note 40 to this subchapter
9903.05.4912.5%Except for products described in headings 9903.05.85–9903.05.92, articles the product of Japan, with an ad valorem (or ad valorem equivalent) rate of duty under column 1 less than 12.5 percent, as provided for in U.S. note 52 to this subchapter
Import Tips
• Include DEA import permit if precursor status applies
• Specify crystalline form (polymorph B typically) in COA
• Provide stability data for transport conditions